Phase 2 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People with a confirmed diagnosis of a solid tumour cancer that has spread (metastatic) or is locally advanced, as seen on standard imaging scans — the specific cancer type depends on which group (cohort) a person is being considered for:
- Group A: Any metastatic solid tumour (the trial is looking for 3 male and 3 female participants in this group)
- Group B: Kidney cancer (any type) or bladder/urinary tract cancer that is locally advanced or metastatic
- Group C: Prostate cancer (adenocarcinoma type) that has spread and is no longer responding to hormone therapy (castration-resistant), meeting specific research criteria
- People in Groups B and C who are planned to receive a type of cancer treatment known as an immune checkpoint inhibitor
- People in Groups B and C who are willing to have two tumour biopsy samples taken and have a tumour in bone or soft tissue that can be safely biopsied
- People aged 18 or older at the time of joining the study
- People who are well enough to carry out daily activities with no or only minor limitations (based on a standard medical performance scale scored 0 or 1)
- People whose kidneys, liver, and blood counts are within acceptable ranges based on blood test results
- People who are willing and able to follow the study procedures and sign a consent form
- Women who could become pregnant must have a negative pregnancy test within 14 days of the PET imaging scan, and both men and women of childbearing potential must use effective contraception
Who may not be able to join:
- People who are currently pregnant or breastfeeding
- People who are unable to give informed consent due to age, a medical or psychiatric condition, or another health-related reason
- People who have any condition that, in the lead investigator's opinion, would prevent them from following the study procedures
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Rahul Aggarwal, MD, University of California, San Francisco
Phone: 877-827-3222
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Frequency of treatment-emergent adverse events (Cohort A); Percent of injected activity (Cohort A); Time to maximum observed concentration (Tmax) (Cohort A); Maximum observed concentration (Cmax) (Cohort A); Area under the concentration-time curve (AUC) (Cohort A); AUC extrapolated to infinity (Cohort A); Median clearance (Cohort A); Apparent terminal elimination rate constant (Cohort A); Apparent terminal elimination half-life (Cohort A); Change in SUVmax (Cohorts B, C, and D); Change in SUVmax/SUVave (Cohorts B, C, and D)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.